Clinical Relevance of Elevated Levels of Serum Soluble Interleukin-2 Receptor alpha (sIL-2Ralpha) in Patients with Non-Hodgkin's Lymphoma.
10.3343/kjlm.2010.30.6.600
- Author:
Seon A JO
1
;
Sang Hyun HWANG
;
Chulhun L CHANG
;
Shine Young KIM
;
Ho Jin SHIN
;
Joo Seop CHUNG
;
Mee Young SOL
;
Eun Yup LEE
Author Information
1. Department of Laboratory Medicine, Pusan National University School of Medicine, Busan, Korea. mindcatch@hanmail.net, eylee@pusan.ac.kr
- Publication Type:Brief Communication ; Research Support, Non-U.S. Gov't
- Keywords:
Soluble interleukin-2 receptor (sIL-2R);
International Prognostic Index;
Non-Hodgkin's lymphoma
- MeSH:
Aged;
Biological Markers/blood;
Female;
Humans;
Interleukin-2 Receptor alpha Subunit/*blood;
L-Lactate Dehydrogenase/blood;
Lymphoma, Non-Hodgkin/*diagnosis/metabolism/mortality;
Male;
Middle Aged;
Neoplasm Staging;
Survival Rate
- From:The Korean Journal of Laboratory Medicine
2010;30(6):600-605
- CountryRepublic of Korea
- Language:English
-
Abstract:
Levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) are known to increase in the sera of patients with certain malignancies, including malignant lymphoma. This study aimed to assess the clinical significance of the sIL-2Ralpha level in non-Hodgkin's lymphoma (NHL). We used ELISA to measure the sIL-2Ralpha levels in 48 newly diagnosed and untreated patients with NHL and evaluated the correlation between the sIL-2Ralpha levels and clinical characteristics and the International Prognostic Index (IPI). We monitored serum sIL-2Ralpha in 7 patients to compare the changes in their clinical progress with these levels. High levels of serum sIL-2Ralpha (> or =2,000 U/mL) correlated well with parameters defining the high risk group according to the IPI, i.e., high tumor burden at diagnosis (stage III+IV) and lactate dehydrogenase > or =472 U/L. The levels were also associated with B symptoms, bone marrow involvement, and poor response to therapy. The sIL-2Ralpha level decreased during complete remission and was elevated during disease progression or relapse. A high level of sIL-2Ralpha was significantly associated with a low survival rate. These results suggest that serum sIL-2Ralpha might be useful as a biomarker for evaluating the prognosis of patients with NHL at the time of diagnosis and during therapy. A well-controlled, large-scale study is needed to clarify the clinical significance of sIL-2Ralpha in specific groups of NHL.
